PERSIA COLEMAN: Open Payments
NPI 1861825341 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$741 in 34 payments from 9 companies in 2025. Trend: 2023 $431 · 2024 $64 · 2025 $741
Food & beverage: $741
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $193 |
| ABBVIE INC. | 9 | $175 |
| Alkermes, Inc. | 4 | $103 |
| Janssen Pharmaceuticals, Inc | 4 | $91 |
| Otsuka America Pharmaceutical, Inc. | 3 | $65 |
| Axsome Therapeutics, Inc. | 2 | $45 |
| Neurocrine BioSciences, Inc. | 1 | $31 |
| Supernus Pharmaceuticals, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
Products named: CAPLYTA, VRAYLAR, ARISTADA, REXULTI, SPRAVATO, Auvelity, INVEGA SUSTENNA, INGREZZA.
Industry payments across NV — which companies pay providers there.
